Insider at

04

Insider transactions

05
0 buys (P) 1 sells (S) Net: $-7,584 + 22 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

22 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Nov. 18, 2025 RCKT S 2,545 $2.98 $7,584 299,064 Direct -0.84% Disposed -14.1% (price as of 2026-10-02)
Aug. 19, 2025 RCKT S 805 $3.00 $2,415 221,609 Direct -0.36% Disposed -14.7% (price as of 2026-10-02)
Aug. 18, 2025 RCKT S 1,680 $3.06 $5,141 222,414 Direct -0.75% Disposed -16.3% (price as of 2026-10-02)
Aug. 14, 2025 RCKT S 11,161 $3.02 $33,706 224,094 Direct -4.74% Disposed -15.2% (price as of 2026-10-02)
May 20, 2025 RCKT S 801 $6.45 $5,166 235,255 Direct -0.34% Disposed -60.3% (price as of 2026-10-02)
May 16, 2025 RCKT S 1,582 $6.53 $10,330 236,056 Direct -0.67% Disposed -60.8% (price as of 2026-10-02)
Feb. 25, 2025 RCKT S 6,532 $10.58 $69,109 237,638 Direct -2.68% Disposed -75.8% (price as of 2026-10-02)
Nov. 21, 2024 RCKT S 3,097 $13.05 $40,416 163,852 Direct -1.86% Disposed -80.4% (price as of 2026-10-02)
Aug. 16, 2024 RCKT S 2,710 $18.50 $50,135 166,949 Direct -1.60% Disposed -86.2% (price as of 2026-10-02)
May 17, 2024 RCKT S 2,754 $23.35 $64,306 169,659 Direct -1.60% Disposed -89.0% (price as of 2026-10-02)
Feb. 17, 2023 RCKT S 3,557 $19.06 $67,796 94,546 Direct -3.63% Disposed -86.6% (price as of 2026-10-02)
April 1, 2022 RCKT S 32,026 $16.20 $518,821 89,529 Direct -26.35% Disposed -84.2% (price as of 2026-10-02)
April 1, 2022 RCKT S 12,974 $15.86 $205,768 121,555 Direct -9.64% Disposed -83.9% (price as of 2026-10-02)
March 31, 2022 RCKT S 35,998 $16.15 $581,368 134,529 Direct -21.11% Disposed -84.1% (price as of 2026-10-02)
March 31, 2022 RCKT S 9,002 $15.90 $143,132 170,527 Direct -5.01% Disposed -83.9% (price as of 2026-10-02)
March 30, 2022 RCKT S 10b5-1 34,438 $16.56 $570,293 179,529 Direct -16.10% Disposed -84.5% (price as of 2026-10-02)
March 30, 2022 RCKT S 10b5-1 10,562 $15.94 $168,358 213,967 Direct -4.70% Disposed -83.9% (price as of 2026-10-02)
March 30, 2022 RCKT S 10b5-1 34,438 $16.56 $570,293 179,529 Direct -16.10% Disposed -84.5% (price as of 2026-10-02)
March 30, 2022 RCKT S 10b5-1 10,562 $15.94 $168,358 213,967 Direct -4.70% Disposed -83.9% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Feb. 11, 2025 RCKT Stock Option (Right to Buy) Common Stock (119,682) $9.88 Feb. 11, 2025 119,682 Acquired
Feb. 14, 2023 RCKT Restricted Stock Units [F1] Common Stock (8,574) · · 8,574 Acquired
Feb. 14, 2023 RCKT Restricted Stock Units Common Stock (41,541) · · 41,541 Acquired
Feb. 14, 2023 RCKT Stock Option (Right to Buy) Common Stock (124,496) $20.04 Feb. 13, 2033 124,496 Acquired
Feb. 14, 2023 RCKT Restricted Stock Units Common Stock (41,541) · · 41,541 Acquired
Feb. 14, 2023 RCKT Stock Option (Right to Buy) Common Stock (124,496) $20.04 Feb. 13, 2033 124,496 Acquired
Aug. 12, 2022 RCKT Restricted Stock Units Common Stock (22,896) · · 22,896 Acquired
Feb. 14, 2022 RCKT Restricted Stock Units Common Stock (25,984) · · 25,984 Acquired
Feb. 14, 2022 RCKT Stock Option (Right to Buy) Common Stock (81,010) $20.00 Feb. 13, 2032 81,010 Acquired
Feb. 4, 2021 RCKT Stock Option (Right to Buy) Common Stock (35,000) $62.32 Feb. 3, 2031 35,000 Acquired
Feb. 1, 2021 RCKT Stock Option (Right to Buy) Common Stock (11,428) $1.69 April 12, 2027 11,428 Disposed
Feb. 10, 2020 RCKT Stock Option (Right to Buy) Common Stock (213,101) $1.21 Feb. 8, 2026 213,101 Disposed
Feb. 10, 2020 RCKT Stock Option (Right to Buy) Common Stock (7,000) $23.89 Feb. 10, 2030 7,000 Acquired
Feb. 6, 2020 RCKT Stock Option (Right to Buy) Common Stock (75,000) $22.72 Feb. 6, 2030 75,000 Acquired
Sept. 2, 2019 RCKT Stock Option (Right to Buy) Common Stock (30,000) $10.85 Sept. 2, 2029 30,000 Acquired
Jan. 28, 2019 RCKT Stock Option (Right to Buy) Common Stock (75,000) $14.56 Jan. 28, 2029 75,000 Acquired
March 29, 2018 RCKT Stock Option (Right to Buy) Common Stock (60,000) $18.75 March 29, 2028 60,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 12 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
April 3, 2024 RCKT Common Stock [F1] 172,413 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (60,000) 60,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (75,000) 75,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (30,000) 30,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (75,000) 75,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (7,000) 7,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (35,000) 35,000 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (81,010) 81,010 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (124,496) 124,496 Direct
April 3, 2024 RCKT Stock Option (Right to Buy) [F3]→ Common Stock (57,273) 57,273 Direct
Jan. 16, 2018 RCKT Stock Option (Right to Buy)→ Common Stock · Direct
Jan. 16, 2018 RCKT Stock Option (Right to Buy)→ Common Stock · Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

RCKT

M.D. Chief Medical and Gene Therapy Officer
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2024 $454,200 · $582,734 $1,167,241 $145,344 · $14,790 $2,364,309
2023 $447,433 · $832,482 $1,667,492 $196,871 · $13,566 $3,157,844
2021 $410,000 $136,530 · $1,324,050 · · $11,265 $1,881,845

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.